Press Releases
- Pulmotect Initiates Landmark Phase 2 Clinical Trial in Immunosuppressed Cancer Patients
July 10, 2025 - Pulmotect Raises $5.9M Series C Round Led by Fannin Partners
September 17, 2024 - Pulmotect Receives First Tranche of $8.9 Million from The State of Texas
November 30, 2023 - Pulmotect Awarded $8.9 Million from The State of Texas
June 6, 2023 - Pulmotect Provides Results from Two Randomized, Placebo Controlled Phase-2 Trials of PUL-042 Against COVID-19
December 2, 2021 - Pulmotect Reports Positive Topline Results from Randomized, Placebo Controlled Phase-2 Trial of PUL-042 against COVID-19
September 21, 2021 - Pulmotect Appoints William J. Noss III as Chief Financial Officer
June 29, 2021 - Pulmotect Awarded Up To $6M From Department of Defense to Complete Two COVID-19 Trials
January 27, 2021 - Pulmotect receives FDA approval to commence two Phase-2 trials targeting COVID-19
May 5, 2020 - Pulmotect’s PUL-042 Shows Promising Pre-Clinical Efficacy in Preventing Lethal Coronavirus Infection
January 27, 2020
More Press Releases
